Monogram Orthopaedics, Inc.
MGRM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -0.19 | -1.43 | -1.00 |
| FCF Yield | -18.20% | -17.65% | -2.52% | -2.96% |
| EV / EBITDA | -3.89 | -3.80 | -32.65 | -33.99 |
| Quality | ||||
| ROIC | -92.76% | -124.33% | -223.00% | -277.19% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 26.99% |
| Cash Conversion Ratio | 0.86 | 0.99 | 0.61 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -16.56% | – | – |
| Free Cash Flow Growth | -3.27% | -57.12% | 14.87% | -50.99% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 0.78 | 0.96 | 0.53 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -474.48 |
| Efficiency | ||||
| Inventory Turnover | 1.49 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -752.07 | 365.00 | -625.98 | -114.18 |